Prostate Cancer - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Prostate Cancer - Pipeline Review, H1 2016

Prostate Cancer - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Prostate Cancer - Pipeline Review, H1 2016
Published Jun 28, 2016
1555 pages — Published Jun 28, 2016
Price US$ 2,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Prostate Cancer - Pipeline Review, H1 2016, provides an overview of the Prostate Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Prostate Cancer
- The report reviews pipeline therapeutics for Prostate Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Prostate Cancer therapeutics and enlists all their major and minor projects
- The report assesses Prostate Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Prostate Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Prostate Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics
-

  
Source:
Document ID
GMDHC7952IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents267
  List of Tables599
  List of Figures681
Introduction691
  Global Markets Direct Report Coverage691
Prostate Cancer Overview701
Therapeutics Development712
  Pipeline Products for Prostate Cancer Overview711
  Pipeline Products for Prostate Cancer Comparative Analysis721
Prostate Cancer Therapeutics under Development by Companies7322
Prostate Cancer Therapeutics under Investigation by Universities/Institutes954
Prostate Cancer Pipeline Products Glance994
  Late Stage Products991
  Clinical Stage Products1001
  Early Stage Products1011
  Unknown Stage Products1021
Prostate Cancer Products under Development by Companies10330
Prostate Cancer Products under Investigation by Universities/Institutes1336
Prostate Cancer Companies Involved in Therapeutics Development139257
  4SC AG1391
  AB Science SA1401
  AbbVie Inc.1411
  Acino International AG1421
  Actinium Pharmaceuticals, Inc.1431
  Adamis Pharmaceuticals Corporation1441
  ADC Therapeutics Sarl1451
  Aduro BioTech, Inc.1461
  Advanced Accelerator Applications S.A.1471
  Advanced Cancer Therapeutics1481
  Advantagene, Inc.1491
  Advaxis, Inc.1501
  Aeglea BioTherapeutics, Inc.1511
  Aeolus Pharmaceuticals, Inc.1521
  Aeterna Zentaris Inc.1531
  Aileron Therapeutics, Inc.1541
  Akshaya Bio Inc.1551
  Alchemia Limited1561
  Alethia Biotherapeutics Inc.1571
  Almac Discovery Limited1581
  Ambrx, Inc.1591
  American Gene Technologies International Inc.1601
  Amgen Inc.1611
  Anavex Life Sciences Corp.1621
  AndroScience Corporation1631
  AnGes MG, Inc.1641
  AntiCancer, Inc.1651
  Antigen Express, Inc.1661
  Antisense Therapeutics Limited1671
  Apac Biotech Pvt Ltd1681
  Apcure SAS1691
  Aphios Corporation1701
  APIM Therapeutics AS1711
  Aptose Biosciences Inc.1721
  Armour Therapeutics Inc.1731
  Arno Therapeutics, Inc.1741
  ArQule, Inc.1751
  Arrien Pharmaceuticals, LLC1761
  Arrowhead Pharmaceuticals, Inc.1771
  Arvinas, Inc.1781
  Asana BioSciences, LLC1791
  Astellas Pharma Inc.1801
  Asterias Biotherapeutics, Inc.1811
  AstraZeneca Plc1821
  ATLAB Pharma SAS1831
  Avipep Pty Ltd1841
  Azaya Therapeutics, Inc.1851
  Bavarian Nordic A/S1861
  Baxalta Incorporated1871
  Bayer AG1881
  Bexion Pharmaceuticals, LLC.1891
  BHR Pharma, LLC1901
  BIND Therapeutics, Inc.1911
  Bio-Cancer Treatment International Limited1921
  Bionature E.A. Ltd.1931
  Biotest AG1941
  Biscayne Pharmaceuticals, Inc.1951
  Blirt S.A.1961
  Boehringer Ingelheim GmbH1971
  Bristol-Myers Squibb Company1981
  Camurus AB1991
  Can-Fite BioPharma Ltd.2001
  CEL-SCI Corporation2011
  Celgene Corporation2021
  CellCentric Ltd2031
  Cellceutix Corporation2041
  Celldex Therapeutics, Inc.2051
  Cellectar Biosciences, Inc.2061
  Celprogen, Inc.2071
  Chamaeleo Pharma NV2081
  CohBar, Inc.2091
  Colby Pharmaceutical Company2101
  Corcept Therapeutics Incorporated2111
  Corvus Pharmaceuticals, Inc.2121
  Crescendo Biologics Limited2131
  CureVac GmbH2141
  CytoVac A/S2151
  CZ BioMed Corp2161
  Deciphera Pharmaceuticals, LLC2171
  DEKK-TEC, Inc.2181
  DexTech Medical AB2191
  Diffusion Pharmaceuticals Inc.2201
  Dongkook Pharmaceutical Co., Ltd.2211
  DormaTarg, Inc.2221
  Eisai Co., Ltd.2231
  Eli Lilly and Company2241
  Emergent BioSolutions Inc.2251
  Enceladus Pharmaceuticals BV2261
  Endo Pharmaceuticals Inc.2271
  EndoCeutics, Inc.2281
  Endocyte, Inc.2291
  EntreChem, S.L.2301
  Errant Gene Therapeutics, LLC2311
  Esperance Pharmaceuticals, Inc.2321
  ESSA Pharma Inc2331
  Eureka Therapeutics, Inc.2341
  Evgen Pharma Plc2351
  Exonate Limited2361
  F. Hoffmann-La Roche Ltd.2371
  Ferring International Center S.A.2381
  Foresee Pharmaceuticals, LLC2391
  Fountain Biopharma Inc.2401
  Fujifilm Corporation2411
  G1 Therapeutics, Inc.2421
  Galectin Therapeutics, Inc.2431
  Genelux Corporation2441
  Genentech, Inc.2451
  Genmab A/S2461
  GenSpera, Inc.2471
  Gilead Sciences, Inc.2481
  Glactone Pharma AB2491
  GlaxoSmithKline Plc2501
  GlycoMimetics, Inc.2511
  GP Pharm, S.A.2521
  GTx, Inc.2531
  Hadasit Medical Research Services &Development Ltd2541
  Hybrigenics S.A.2551
  IC-MedTech, Inc.2561
  Ideaya Biosciences, Inc.2571
  IGF Oncology, LLC.2581
  Ignyta, Inc.2591
  Immune Pharmaceuticals Inc.2601
  Immuneed AB2611
  Immunocore Limited2621
  ImmunoFrontier, Inc.2631
  Immunomedics, Inc.2641
  Immupharma Plc2651
  Incanthera Ltd.2661
  Incuron, LLC2671
  Innate Immunotherapeutics Ltd2681
  Inovio Pharmaceuticals, Inc.2691
  Io Therapeutics, Inc.2701
  Ipsen S.A.2711
  Jiangsu Hengrui Medicine Co., Ltd.2721
  Johnson &Johnson2731
  Jyant Technologies, Inc.2741
  KaloBios Pharmaceuticals, Inc.2751
  Karyopharm Therapeutics, Inc.2761
  Kite Pharma, Inc.2771
  Komipharm International Co., Ltd.2781
  Kura Oncology, Inc.2791
  Kyowa Hakko Kirin Co., Ltd.2801
  Lidds AB2811
  Luye Pharma Group Ltd.2821
  MacroGenics, Inc.2831
  Mallinckrodt Plc2841
  MaxiVAX SA2851
  Meabco A/S2861
  Mebiopharm Co., Ltd.2871
  MediaPharma s.r.l.2881
  Medicenna Therapeutics, Inc.2891
  MediGene AG2901
  MedImmune, LLC2911
  Mediolanum farmaceutici S.p.A.2921
  Medivation, Inc.2931
  MEI Pharma, Inc.2941
  Merck &Co., Inc.2951
  Merck KGaA2961
  Millennium Pharmaceuticals, Inc.2971
  Minerva Biotechnologies Corporation2981
  Mirna Therapeutics, Inc.2991
  Mithra Pharmaceuticals S.A.3001
  MolMed S.p.A.3011
  Monopar Therapeutics LLC3021
  Morphotek, Inc.3031
  NewLink Genetics Corporation3041
  NormOxys, Inc.3051
  Novartis AG3061
  Novogen Limited3071
  Nymox Pharmaceutical Corporation3081
  Oasmia Pharmaceutical AB3091
  Omeros Corporation3101
  Omnitura Therapeutics Inc.3111
  OncBioMune Pharmaceuticals Inc.3121
  Oncodrone BV3131
  Oncogenex Pharmaceuticals, Inc.3141
  Oncolix, Inc.3151
  Oncolytics Biotech Inc.3161
  OncoMax3171
  OncoNOx ApS3181
  OncoTartis, Inc.3191
  Oncovir, Inc.3201
  OncoVista Innovative Therapies, Inc.3211
  ORCA Therapeutics B.V.3221
  Oribase Pharma3231
  Orion Oyj3241
  Orphagen Pharmaceuticals, Inc.3251
  Otsuka Holdings Co., Ltd.3261
  OXiGENE, Inc.3271
  Panacela Labs, Inc.3281
  PDS Biotechnology Corporation3291
  Peptron, Inc.3301
  Pfizer Inc.3311
  Pharmedartis GmbH3321
  Pharmicell Co., Ltd.3331
  Pharminox Limited3341
  Polaris Pharmaceuticals, Inc.3351
  Polyplus-Transfection SA3361
  Prima BioMed Ltd.3371
  Princeton University3381
  Progenics Pharmaceuticals, Inc.3391
  Provectus Biopharmaceuticals, Inc.3401
  Provenance Biopharmaceuticals Corp.3411
  PSites Pharma GmbH3421
  Qu Biologics Inc.3431
  Quest PharmaTech Inc.3441
  RedHill Biopharma Ltd.3451
  Rexahn Pharmaceuticals, Inc.3461
  Rigontec GmbH3471
  Sanofi3481
  Sareum Holdings Plc3491
  SEEK Group3501
  Serometrix, LLC3511
  Shenogen Pharma Group Ltd.3521
  Snowdon Inc.3531
  Sophiris Bio, Inc.3541
  Soricimed Biopharma Inc.3551
  Sorrento Therapeutics, Inc.3561
  Sotio a.s.3571
  Stemline Therapeutics, Inc.3581
  Sunesis Pharmaceuticals, Inc.3591
  Supratek Pharma Inc.3601
  Synta Pharmaceuticals Corp.3611
  TaiGen Biotechnology Co., Ltd.3621
  Taiho Pharmaceutical Co., Ltd.3631
  Taiwan Liposome Company, Ltd.3641
  Takeda Pharmaceutical Company Limited3651
  Takis S.r.l.3661
  Targovax AS3671
  Tesaro, Inc.3681
  Teva Pharmaceutical Industries Ltd.3691

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Prostate Cancer - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Prostate-Cancer-Pipeline-Review-H1-2016-2088-16013>
  
APA:
Global Markets Direct - Market Research. (2016). Prostate Cancer - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Prostate-Cancer-Pipeline-Review-H1-2016-2088-16013>
  
US$ 2,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.